Amiens Cedex 1

• INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting
  2024-511989-36-00 5 2025-09-24 Ewing Sarcoma
• Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial … Recruiting
  2023-510099-30-00 5 2025-09-23 Out-of-hospital cardiac arrest with initial shockable rhythm
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• Effect of long-term carvedilol to prevent decompensation or death in patients with asymptomatic Child-Pugh A5 to B8 cirrhosis and clinically … Recruiting
  2024-511663-28-00 6 2025-09-11 Asymptomatic Child-Pugh A5 to B8 cirrhosis
• Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting
  2024-515875-36-00 4 2025-08-18 Advanced biliary tract cancer (BTC)
• Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in patients at high risk of postoperative pulmonary complications Recruiting
  2023-510564-12-00 5 2025-08-14 postoperative pulmonary complications
• Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo … Recruiting
  2024-515349-41-00 4 2025-07-29 Metastatic Breast Cancer HR+, HER2-
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• metastatic colorectal cancer Recruiting
  2023-504831-42-00 5 2025-06-27 patient with colorectal cancer with hepatic metastasis
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p … Recruiting
  2024-517996-19-00 4 2025-06-19 Primary premature ejaculation
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 6 2025-06-16 Rheumatoid arthritis
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re … Recruiting
  2024-516650-22-00 6 2025-05-16 Renal carcinoma
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting
  2024-511495-32-00 5 2025-04-16 Chronic Phase Chronic Myeloid Leukemia
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly Recruiting
  2024-513084-38-00 9 2025-04-15 Recently diagnosed non favorable Acute Myeloid Leukemias
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting
  2024-512729-10-00 4 2025-03-27 Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 Triple Negative Breast Cancer with residual disease after neoadjuvant

Showing 121–144 of 328 trials